← Map · Health Care Equipment · S&P SmallCap 600
TFX TELEFLEX $5.2B
No. A live contouring model, inside a business being sold.
7 of 15
Reach, Weight, and Proof.
What they are doing
Teleflex put an AI contouring model for its Barrigel rectal spacer into Radformation AutoContour, FDA-cleared in March 2026 and announced 23 July 2026. The model was trained on Barrigel trial scans. That is a real tool in radiation planning. It sits in Interventional Urology, which Teleflex has agreed to sell. The annual report also says the supply chain harnesses analytics and AI, with the cited complaint and backlog results credited to the analytics team rather than to a named model.
Why the score
- Reach 2 not 3: the spacer model plus a supply-chain analytics effort. Not a third function.
- Weight 2 not 3: contouring catches up to a tool a rival spacer already has, and the unit is leaving.
- Proof 3 not 4: FDA-cleared and trained on their trial. No result a manager would recognize on the model itself.
What would move it next quarter: A result on contouring time or plan quality, in a business Teleflex is keeping. The sale closing will not raise this.
Open these first
Evidence
Barrigel rectal spacer is now a contouring option in Radformation AutoContour v2.7. The software was FDA-cleared in March 2026. The AI model was trained on MRI and CT scans from the Barrigel pivotal trial. Interventional Urology is preparing for divestiture in the second half of 2026.
The supply chain is described as harnessing advanced analytics and artificial intelligence. The analytics team outlined a strategy to use machine learning and AI. Complaint alerts and a lower backlog are credited to that team, not to a named model.